News Network: Prostate Cancer at SUO 2025

One notable trend is the shift of therapies originally reserved for heavily pretreated, castration-resistant prostate cancer into earlier phases of disease.

Stratton emphasized that the trial’s results provide greater confidence in recommending therapy and allow clinicians to counsel patients more decisively about next steps when PSA begins to rise.

TULSA patients were treated and discharged the same day.

For patients undergoing salvage surgery or radiation, Kelly L. Stratton, MD, FACS, notes that previous focal therapy can influence outcomes.

Arvin K. George, MD, discusses the unique design of the VAPOR 2 trial as well as the key findings from the first 110 patients enrolled in the study.

The primary end point is overall survival, with secondary end points including PSA response metrics, progression measures, PSA kinetics, and several ctDNA assessments to help identify which patients benefit most.